- Report
- January 2022
- 200 Pages
Global
From €7284EUR$7,500USD£6,223GBP
- Report
- August 2022
Global
From €1059EUR$1,090USD£904GBP
- Report
- February 2021
Global
From €2875EUR$2,960USD£2,456GBP
- Report
- February 2023
- 834 Pages
Global
From €2428EUR$2,500USD£2,074GBP
- Clinical Trials
- May 2020
- 735 Pages
Global
From €2428EUR$2,500USD£2,074GBP
- Report
- November 2018
- 43 Pages
Global
From €3880EUR$3,995USD£3,315GBP
- Report
- November 2018
- 164 Pages
Global
From €10679EUR$10,995USD£9,123GBP
- Report
- November 2023
- 90 Pages
Global
From €3500EUR$3,860USD£3,095GBP
- Report
- May 2023
- 93 Pages
Global
From €3500EUR$3,860USD£3,095GBP
- Report
- September 2022
- 383 Pages
Global
From €2428EUR$2,500USD£2,074GBP
- Report
- May 2022
- 35 Pages
Global
From €1942EUR$2,000USD£1,660GBP
- Drug Pipelines
- November 2020
- 407 Pages
Global
From €2428EUR$2,500USD£2,074GBP
From €125EUR$129USD£107GBP
- Book
- September 2022
- 400 Pages
- Book
- May 2016
- 320 Pages
The Malaria Drug market is a subset of the larger Infectious Diseases Drugs market. Malaria is a mosquito-borne disease caused by a parasite, and is one of the leading causes of death in the world. Malaria drugs are used to treat and prevent the disease, and are typically administered orally or intravenously. The market for malaria drugs is highly competitive, with a range of generic and branded products available. The market is driven by the increasing prevalence of malaria, as well as the need for new and improved treatments.
The market is also influenced by government policies and regulations, as well as the availability of funding for research and development. Additionally, the market is affected by the availability of new technologies, such as rapid diagnostic tests and vaccines.
Some companies in the Malaria Drug market include Novartis, GlaxoSmithKline, Sanofi, Merck, and Pfizer. Show Less Read more
